Changeflow GovPing Healthcare & Life Sciences Isotopically enriched psychedelic analogs for b...
Routine Notice Added Draft

Isotopically enriched psychedelic analogs for brain disorders

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO published patent application US20260092060A1 for isotopically enriched analogs of 2-bromo-LSD, LSD, ALD-52, and 1P-LSD developed by inventors Matthew Duncton and Samuel Clark. The compounds are directed toward treating neurologic and brain disorders. The application was filed on June 5, 2025, under Application No. 19228993.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO published a patent application covering isotopically enriched variants of classic psychedelic compounds including 2-bromo-LSD, LSD, ALD-52, and 1P-LSD. The claimed inventions include novel chemical compositions and methods for their use in treating neurologic and brain disorders. The patent is classified under CPC codes including C07D 457/06 (lysergic acid derivatives), A61K 31/48, A61P 25/28, and A61P 25/32 covering nervous system and neurological disorder treatments.

Pharmaceutical companies and researchers developing psychedelic-based therapeutics should review this application to assess potential freedom-to-operate considerations and competitive landscape. This represents an emerging patent filing in the psychedelic medicine space targeting neurological applications. No immediate compliance actions are required as this is a pending patent application, not an issued patent or regulatory requirement.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

ISOTOPICALLY ENRICHED ANALOGS OF 2-BROMO-LSD, LSD, ALD-52, AND 1P-LSD

Application US20260092060A1 Kind: A1 Apr 02, 2026

Inventors

Matthew DUNCTON, Samuel CLARK

Abstract

Disclosed herein are isotopically enriched compounds of 2-bromolysergic acid diethylamide, LSD, ALD-52, and 1P-LSD, as well as methods for their use in treating neurologic and brain disorders.

CPC Classifications

C07D 457/06 A61K 31/36 A61K 31/48 A61K 31/517 A61P 25/28 A61P 25/32

Filing Date

2025-06-05

Application No.

19228993

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260092060A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Patients
Industry sector
3254 Pharmaceutical Manufacturing 6211 Healthcare Providers
Activity scope
Patent Filings Drug Development Neurological Treatment Research
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Legal
Topics
Intellectual Property Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!